Carbatrol Capsule, Extended Release
Product Images NDC 54092-172

Product Visual Gallery

This gallery contains 4 technical images submitted to the FDA as part of the official labeling for Carbatrol (NDC 54092-172). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Takeda Pharmaceuticals America, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Carbatrol-figure-1 (Carbatrol 01)

Carbamazepine is a medication used for the treatment of epilepsy, neuropathic pain, and bipolar disorder. It works by decreasing abnormal activity in the brain. It is available in various forms, including tablets, extended-release tablets, and suspension. It is important to follow the dosage instructions carefully and to consult a healthcare provider before taking this medication.*

FDA Label Image

Principal Display Panel (100 mg Capsule Bottle Label)

This is a medication called "Arbatrol HiE," which contains the active ingredient carbamazepine and comes in extended-release capsules. It should not be used with other carbamazepine-containing products. The medication is distributed by Takeda Pharmaceuticals America, Inc. and is dispensed with a medication guide for patients.*

FDA Label Image

Principal Display Panel (200 mg Capsule Bottle Label)

Carbatrol’ is a medication distributed by Takeda Pharmaceuticals America, Inc. in the form of capsules containing products. The item code for this medication is NDG 540217212. It is intended for medical personnel use only as indicated by "Rx only" and should not be used with other carbamazepine. The text also includes some unintelligible parts and characters.*

FDA Label Image

Principal Display Panel (300 mg Capsule Bottle Label)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.